auto-fix: strip 1 broken wiki links

Pipeline auto-fixer: removed [[ ]] brackets from links
that don't resolve to existing claims in the knowledge base.

domains/health/glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation.md

@@ -39,3 +39,17 @@ Target trial emulation (real-world data) shows semaglutide associated with signi
 **Source:** Hendershot et al., JAMA Psychiatry 2025
 
 Phase 2 RCT (n=48, 9 weeks) showed dose-dependent effects on alcohol use disorder: small-to-medium effects at 0.25mg escalating to large effect sizes (Cohen d > 0.80) at 0.5mg for heavy drinking days and drinks per drinking day. Laboratory self-administration showed β=−0.48 for grams consumed (p=0.01) and β=−0.46 for peak BrAC (p=0.03). Alcohol craving reduced significantly (β=−0.39, p=0.01). Cigarette consumption in smokers (n=13) also reduced significantly (p=0.005), suggesting broad reward circuit effects.
+
+
+## Supporting Evidence
+
+**Source:** eClinicalMedicine (Lancet) 2025 systematic review and meta-analysis
+
+Meta-analysis of 14 studies (n=5,262,278) shows pooled AUDIT score reduction of −7.81 points (95% CI −9.02 to −6.60), which is clinically meaningful (moves patients from hazardous to non-hazardous drinking). Pooled observational studies show HR 0.64 (95% CI 0.59–0.69) for alcohol-related events — 36% lower rate. Individual RCTs with semaglutide show significant effects, though pooled RCT analysis is non-significant due to heterogeneity (I²=87.5%) and small-sample pooling. Semaglutide and liraglutide showed strongest and most consistent reductions across studies.
+
+
+## Extending Evidence
+
+**Source:** Qeadan F et al., Addiction 2025
+
+Qeadan et al. (2025) retrospective cohort study of 1.3M patients across 136 US health systems found GLP-1 RA prescriptions associated with 40% lower opioid overdose rates (IRR 0.60, 95% CI 0.43-0.83) in OUD cohort and 50% lower alcohol intoxication rates (IRR 0.50, 95% CI 0.40-0.63) in AUD cohort over 24-month follow-up. Effects consistent across T2DM, obesity, and combined subgroups. This is the largest-scale human data on GLP-1 for opioid outcomes, though observational design creates substantial healthy user bias concerns (patients receiving GLP-1 are more healthcare-engaged, financially able, and motivated). The consistency across subgroups (whether prescribed for diabetes or obesity) reduces some confounding concern. Published in Addiction (Wiley) with formal commentary noting need for prospective RCTs.

domains/health/semaglutide-produces-large-effect-aud-reduction-through-vta-dopamine-suppression.md

@@ -11,9 +11,23 @@ sourced_from: health/2026-04-24-hendershot-jama-psychiatry-semaglutide-aud-rct.m
 scope: causal
 sourcer: Hendershot CS et al.
 supports: ["glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation", "behavioral-biological-health-dichotomy-false-for-reward-dysregulation-conditions"]
-related: ["hedonic-eating-dopamine-circuit-adapts-to-glp1-suppression-explaining-continuous-delivery-requirement", "glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation", "behavioral-biological-health-dichotomy-false-for-reward-dysregulation-conditions", "real-world-semaglutide-shows-stronger-mace-reduction-than-select-trial"]
+related: ["hedonic-eating-dopamine-circuit-adapts-to-glp1-suppression-explaining-continuous-delivery-requirement", "glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation", "behavioral-biological-health-dichotomy-false-for-reward-dysregulation-conditions", "real-world-semaglutide-shows-stronger-mace-reduction-than-select-trial", "semaglutide-produces-large-effect-aud-reduction-through-vta-dopamine-suppression"]
 ---
 
 # Semaglutide produces large-effect-size reductions in alcohol consumption and craving through VTA dopamine reward circuit suppression
 
 A 9-week double-blind RCT (n=48) demonstrated that semaglutide produces clinically significant reductions in alcohol consumption through the same VTA dopamine reward circuit mechanism that drives its metabolic effects. The trial showed dose-response escalation: small-to-medium effects at 0.25mg (weeks 1-4), but large effect sizes (Cohen d > 0.80) at 0.5mg (weeks 5-8) for both heavy drinking days and drinks per drinking day. Laboratory alcohol self-administration showed medium-large effects (β=−0.48 grams consumed, p=0.01; β=−0.46 peak BrAC, p=0.03). Weekly alcohol craving showed significant reduction (β=−0.39, p=0.01). The dose-response relationship is critical evidence: if this were placebo effect or behavioral confounding, effect size would not systematically increase with dose. The mechanism is biologically grounded—semaglutide suppresses VTA dopamine activity, the same pathway mediating food reward and hedonic eating. Notably, the trial also found significant cigarette reduction in the smoker subgroup (n=13, p=0.005), suggesting broad reward circuit effects beyond alcohol. Limitations: Phase 2 only, 9-week duration, non-treatment-seeking participants with moderate AUD severity, and 1.0mg dose reached only in final week. No abstinence endpoints measured. Phase 3 trials now underway.
+
+
+## Supporting Evidence
+
+**Source:** eClinicalMedicine (Lancet) 2025 systematic review
+
+Meta-analysis confirms semaglutide as best-performing agent for alcohol reduction across 14 studies. The −7.81 point AUDIT reduction represents movement from hazardous to non-hazardous drinking levels. Individual semaglutide RCTs (including Hendershot 2025) each show significant effects, with reductions in drinking days, units per drinking day, and cravings.
+
+
+## Supporting Evidence
+
+**Source:** Qeadan F et al., Addiction 2025
+
+Real-world observational data from 817,309 AUD patients (5,621 with GLP-1 RA) shows 50% lower alcohol intoxication rates (IRR 0.50, 95% CI 0.40-0.63) over 24 months, consistent with Hendershot RCT findings. Effect maintained across T2DM (IRR 0.51), obesity (IRR 0.58), and combined conditions (IRR 0.58) subgroups. Provides population-scale corroboration of the VTA dopamine mechanism hypothesis, though observational confounding limits causal inference.

domains/health/us-healthcare-spending-outcome-paradox-confirms-non-clinical-factors-dominate-population-health.md

@@ -26,6 +26,17 @@ related: ["medical care explains only 10-20 percent of health outcomes because b
 
 OECD 2025 data confirms the spending-outcome paradox with precise international benchmarking: US spends $14,885 per capita (2.5x OECD average $5,967) and 17.2% of GDP (vs 9.3% OECD average), yet life expectancy is 78.4 years—2.7 years below OECD average. The preventable mortality gap (50% worse than OECD) is more than double the treatable mortality gap (23% worse), demonstrating that the primary failure is non-clinical. US clinical care quality is internationally competitive on acute conditions (AMI, stroke), but behavioral and social determinants drive the aggregate underperformance.
 
+
+### Auto-enrichment (near-duplicate conversion, similarity=1.00)
+*Source: PR #3929 — "us healthcare spending outcome paradox confirms non clinical factors dominate population health"*
+*Auto-converted by substantive fixer. Review: revert if this evidence doesn't belong here.*
+
+## Supporting Evidence
+
+**Source:** OECD Health at a Glance 2025
+
+OECD 2025 data quantifies the spending-outcome paradox with precision: US per capita spending is $14,885 (2.5x OECD average $5,967), GDP share 17.2% vs 9.3%, yet life expectancy is 2.7 years below OECD average (78.4 vs ~81.1 years). The preventable mortality gap (50% worse than OECD) is more than double the treatable mortality gap (23% worse), demonstrating that the primary failure is non-clinical. US acute care quality (AMI, stroke) meets or exceeds OECD standards, confirming the paradox is not about clinical capability but about behavioral and social determinants.
+
 ---
 
 # The US healthcare spending/outcome paradox — world-class acute care outcomes with dramatically worse preventable mortality — is the strongest empirical confirmation that non-clinical factors dominate population health

inbox/archive/health/2026-04-24-eclinmed-glp1-alcohol-meta-analysis-2025.md

@@ -7,9 +7,12 @@ date: 2025
 domain: health
 secondary_domains: []
 format: peer-reviewed study
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-04-24
 priority: high
 tags: [glp-1, alcohol-use-disorder, AUD, meta-analysis, systematic-review, semaglutide, liraglutide, AUDIT, addiction, reward-circuit]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content

inbox/archive/health/2026-04-24-qeadan-addiction-glp1-oud-aud-real-world.md

@@ -7,9 +7,12 @@ date: 2025-02-01
 domain: health
 secondary_domains: []
 format: peer-reviewed study
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-04-24
 priority: high
 tags: [glp-1, GIP, semaglutide, opioid-use-disorder, alcohol-use-disorder, AUD, OUD, addiction, real-world-data, observational, reward-circuit]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content